Eintrag weiter verarbeiten
Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a...
Gespeichert in:
| Zeitschriftentitel: | BMJ Open |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | BMJ Open, 9, 2019, 7, S. e026975 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
BMJ
|
| Schlagwörter: |
| author_facet |
Gonçalves, Caroline Amélia Lopes-Júnior, Luís Carlos Nampo, Fernando Kenji Zilly, Adriana Mayer, Paulo César Morales Pereira-da-Silva, Gabriela Gonçalves, Caroline Amélia Lopes-Júnior, Luís Carlos Nampo, Fernando Kenji Zilly, Adriana Mayer, Paulo César Morales Pereira-da-Silva, Gabriela |
|---|---|
| author |
Gonçalves, Caroline Amélia Lopes-Júnior, Luís Carlos Nampo, Fernando Kenji Zilly, Adriana Mayer, Paulo César Morales Pereira-da-Silva, Gabriela |
| spellingShingle |
Gonçalves, Caroline Amélia Lopes-Júnior, Luís Carlos Nampo, Fernando Kenji Zilly, Adriana Mayer, Paulo César Morales Pereira-da-Silva, Gabriela BMJ Open Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol General Medicine |
| author_sort |
gonçalves, caroline amélia |
| spelling |
Gonçalves, Caroline Amélia Lopes-Júnior, Luís Carlos Nampo, Fernando Kenji Zilly, Adriana Mayer, Paulo César Morales Pereira-da-Silva, Gabriela 2044-6055 2044-6055 BMJ General Medicine http://dx.doi.org/10.1136/bmjopen-2018-026975 <jats:sec><jats:title>Introduction</jats:title><jats:p>Eighty per cent of the sexually active population will get human papillomavirus (HPV) infection, which is the most prevalent sexually transmitted disease worldwide. Persistence of high-grade HPV infection may evolve to a cervical intraepithelial neoplasia (CIN), and these lesions may be precursors of cervical cancer. However, this progression can be prevented by the administration of therapeutic vaccines which use the main oncoproteins responsible for cancer development in an attempt to trigger a more specific and effective immunological response against this disorder. We aim to evaluate the safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade CIN 2/3 associated with HPV.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>A systematic review of clinical trials will be undertaken. Medline, Excerpta Medica Database, Cochrane Central Register of Controlled Trials, Web of Science, Latin American and Caribbean Health Sciences Literature, Scientific Electronic Library Online and Scopus will be searched, with no restriction regarding publication date. Primary outcomes will include measures related to safety, efficacy and the immunogenicity of the therapeutic vaccines used in these patients. Study selection will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Methodological appraisal of the studies will be assessed by the Cochrane Risk-of-Bias Tool for randomised controlled trials, and the quality evidence of the risk of bias in single studies will be evaluated by Grading of Recommendations Assessment, Development and Evaluation. A narrative synthesis will be done for all included studies. Outcomes will be analysed according to the subgroups of HPV type, CIN grade, route of vaccine administration and vaccine type. Also, if sufficient data are available, a meta-analysis will be conducted. The effect sizes will be generated using Hedges’ g score for both fixed and random effect models. I<jats:sup>2</jats:sup>statistics will be used to assess heterogeneity and identify their potential sources.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>Ethical approval is not required as primary data will not be collected. Findings will be disseminated widely via peer-reviewed publication and in different media, for example, conferences, congresses or symposia.</jats:p></jats:sec><jats:sec><jats:title>PROSPERO registration number</jats:title><jats:p>CRD42017077428.</jats:p></jats:sec> Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol BMJ Open |
| doi_str_mv |
10.1136/bmjopen-2018-026975 |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEzNi9ibWpvcGVuLTIwMTgtMDI2OTc1 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEzNi9ibWpvcGVuLTIwMTgtMDI2OTc1 |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
BMJ, 2019 |
| imprint_str_mv |
BMJ, 2019 |
| issn |
2044-6055 |
| issn_str_mv |
2044-6055 |
| language |
English |
| mega_collection |
BMJ (CrossRef) |
| match_str |
goncalves2019safetyefficacyandimmunogenicityoftherapeuticvaccinesinthetreatmentofpatientswithhighgradecervicalintraepithelialneoplasiaassociatedwithhumanpapillomavirusasystematicreviewprotocol |
| publishDateSort |
2019 |
| publisher |
BMJ |
| recordtype |
ai |
| record_format |
ai |
| series |
BMJ Open |
| source_id |
49 |
| title |
Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_unstemmed |
Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_full |
Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_fullStr |
Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_full_unstemmed |
Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_short |
Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_sort |
safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| topic |
General Medicine |
| url |
http://dx.doi.org/10.1136/bmjopen-2018-026975 |
| publishDate |
2019 |
| physical |
e026975 |
| description |
<jats:sec><jats:title>Introduction</jats:title><jats:p>Eighty per cent of the sexually active population will get human papillomavirus (HPV) infection, which is the most prevalent sexually transmitted disease worldwide. Persistence of high-grade HPV infection may evolve to a cervical intraepithelial neoplasia (CIN), and these lesions may be precursors of cervical cancer. However, this progression can be prevented by the administration of therapeutic vaccines which use the main oncoproteins responsible for cancer development in an attempt to trigger a more specific and effective immunological response against this disorder. We aim to evaluate the safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade CIN 2/3 associated with HPV.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>A systematic review of clinical trials will be undertaken. Medline, Excerpta Medica Database, Cochrane Central Register of Controlled Trials, Web of Science, Latin American and Caribbean Health Sciences Literature, Scientific Electronic Library Online and Scopus will be searched, with no restriction regarding publication date. Primary outcomes will include measures related to safety, efficacy and the immunogenicity of the therapeutic vaccines used in these patients. Study selection will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Methodological appraisal of the studies will be assessed by the Cochrane Risk-of-Bias Tool for randomised controlled trials, and the quality evidence of the risk of bias in single studies will be evaluated by Grading of Recommendations Assessment, Development and Evaluation. A narrative synthesis will be done for all included studies. Outcomes will be analysed according to the subgroups of HPV type, CIN grade, route of vaccine administration and vaccine type. Also, if sufficient data are available, a meta-analysis will be conducted. The effect sizes will be generated using Hedges’ g score for both fixed and random effect models. I<jats:sup>2</jats:sup>statistics will be used to assess heterogeneity and identify their potential sources.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>Ethical approval is not required as primary data will not be collected. Findings will be disseminated widely via peer-reviewed publication and in different media, for example, conferences, congresses or symposia.</jats:p></jats:sec><jats:sec><jats:title>PROSPERO registration number</jats:title><jats:p>CRD42017077428.</jats:p></jats:sec> |
| container_issue |
7 |
| container_start_page |
0 |
| container_title |
BMJ Open |
| container_volume |
9 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347287175823371 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:51:26.144Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Safety%2C+efficacy+and+immunogenicity+of+therapeutic+vaccines+in+the+treatment+of+patients+with+high-grade+cervical+intraepithelial+neoplasia+associated+with+human+papillomavirus%3A+a+systematic+review+protocol&rft.date=2019-07-01&genre=article&issn=2044-6055&volume=9&issue=7&pages=e026975&jtitle=BMJ+Open&atitle=Safety%2C+efficacy+and+immunogenicity+of+therapeutic+vaccines+in+the+treatment+of+patients+with+high-grade+cervical+intraepithelial+neoplasia+associated+with+human+papillomavirus%3A+a+systematic+review+protocol&aulast=Pereira-da-Silva&aufirst=Gabriela&rft_id=info%3Adoi%2F10.1136%2Fbmjopen-2018-026975&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347287175823371 |
| author | Gonçalves, Caroline Amélia, Lopes-Júnior, Luís Carlos, Nampo, Fernando Kenji, Zilly, Adriana, Mayer, Paulo César Morales, Pereira-da-Silva, Gabriela |
| author_facet | Gonçalves, Caroline Amélia, Lopes-Júnior, Luís Carlos, Nampo, Fernando Kenji, Zilly, Adriana, Mayer, Paulo César Morales, Pereira-da-Silva, Gabriela, Gonçalves, Caroline Amélia, Lopes-Júnior, Luís Carlos, Nampo, Fernando Kenji, Zilly, Adriana, Mayer, Paulo César Morales, Pereira-da-Silva, Gabriela |
| author_sort | gonçalves, caroline amélia |
| container_issue | 7 |
| container_start_page | 0 |
| container_title | BMJ Open |
| container_volume | 9 |
| description | <jats:sec><jats:title>Introduction</jats:title><jats:p>Eighty per cent of the sexually active population will get human papillomavirus (HPV) infection, which is the most prevalent sexually transmitted disease worldwide. Persistence of high-grade HPV infection may evolve to a cervical intraepithelial neoplasia (CIN), and these lesions may be precursors of cervical cancer. However, this progression can be prevented by the administration of therapeutic vaccines which use the main oncoproteins responsible for cancer development in an attempt to trigger a more specific and effective immunological response against this disorder. We aim to evaluate the safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade CIN 2/3 associated with HPV.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>A systematic review of clinical trials will be undertaken. Medline, Excerpta Medica Database, Cochrane Central Register of Controlled Trials, Web of Science, Latin American and Caribbean Health Sciences Literature, Scientific Electronic Library Online and Scopus will be searched, with no restriction regarding publication date. Primary outcomes will include measures related to safety, efficacy and the immunogenicity of the therapeutic vaccines used in these patients. Study selection will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Methodological appraisal of the studies will be assessed by the Cochrane Risk-of-Bias Tool for randomised controlled trials, and the quality evidence of the risk of bias in single studies will be evaluated by Grading of Recommendations Assessment, Development and Evaluation. A narrative synthesis will be done for all included studies. Outcomes will be analysed according to the subgroups of HPV type, CIN grade, route of vaccine administration and vaccine type. Also, if sufficient data are available, a meta-analysis will be conducted. The effect sizes will be generated using Hedges’ g score for both fixed and random effect models. I<jats:sup>2</jats:sup>statistics will be used to assess heterogeneity and identify their potential sources.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>Ethical approval is not required as primary data will not be collected. Findings will be disseminated widely via peer-reviewed publication and in different media, for example, conferences, congresses or symposia.</jats:p></jats:sec><jats:sec><jats:title>PROSPERO registration number</jats:title><jats:p>CRD42017077428.</jats:p></jats:sec> |
| doi_str_mv | 10.1136/bmjopen-2018-026975 |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEzNi9ibWpvcGVuLTIwMTgtMDI2OTc1 |
| imprint | BMJ, 2019 |
| imprint_str_mv | BMJ, 2019 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 2044-6055 |
| issn_str_mv | 2044-6055 |
| language | English |
| last_indexed | 2024-03-01T17:51:26.144Z |
| match_str | goncalves2019safetyefficacyandimmunogenicityoftherapeuticvaccinesinthetreatmentofpatientswithhighgradecervicalintraepithelialneoplasiaassociatedwithhumanpapillomavirusasystematicreviewprotocol |
| mega_collection | BMJ (CrossRef) |
| physical | e026975 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | BMJ |
| record_format | ai |
| recordtype | ai |
| series | BMJ Open |
| source_id | 49 |
| spelling | Gonçalves, Caroline Amélia Lopes-Júnior, Luís Carlos Nampo, Fernando Kenji Zilly, Adriana Mayer, Paulo César Morales Pereira-da-Silva, Gabriela 2044-6055 2044-6055 BMJ General Medicine http://dx.doi.org/10.1136/bmjopen-2018-026975 <jats:sec><jats:title>Introduction</jats:title><jats:p>Eighty per cent of the sexually active population will get human papillomavirus (HPV) infection, which is the most prevalent sexually transmitted disease worldwide. Persistence of high-grade HPV infection may evolve to a cervical intraepithelial neoplasia (CIN), and these lesions may be precursors of cervical cancer. However, this progression can be prevented by the administration of therapeutic vaccines which use the main oncoproteins responsible for cancer development in an attempt to trigger a more specific and effective immunological response against this disorder. We aim to evaluate the safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade CIN 2/3 associated with HPV.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>A systematic review of clinical trials will be undertaken. Medline, Excerpta Medica Database, Cochrane Central Register of Controlled Trials, Web of Science, Latin American and Caribbean Health Sciences Literature, Scientific Electronic Library Online and Scopus will be searched, with no restriction regarding publication date. Primary outcomes will include measures related to safety, efficacy and the immunogenicity of the therapeutic vaccines used in these patients. Study selection will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Methodological appraisal of the studies will be assessed by the Cochrane Risk-of-Bias Tool for randomised controlled trials, and the quality evidence of the risk of bias in single studies will be evaluated by Grading of Recommendations Assessment, Development and Evaluation. A narrative synthesis will be done for all included studies. Outcomes will be analysed according to the subgroups of HPV type, CIN grade, route of vaccine administration and vaccine type. Also, if sufficient data are available, a meta-analysis will be conducted. The effect sizes will be generated using Hedges’ g score for both fixed and random effect models. I<jats:sup>2</jats:sup>statistics will be used to assess heterogeneity and identify their potential sources.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>Ethical approval is not required as primary data will not be collected. Findings will be disseminated widely via peer-reviewed publication and in different media, for example, conferences, congresses or symposia.</jats:p></jats:sec><jats:sec><jats:title>PROSPERO registration number</jats:title><jats:p>CRD42017077428.</jats:p></jats:sec> Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol BMJ Open |
| spellingShingle | Gonçalves, Caroline Amélia, Lopes-Júnior, Luís Carlos, Nampo, Fernando Kenji, Zilly, Adriana, Mayer, Paulo César Morales, Pereira-da-Silva, Gabriela, BMJ Open, Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol, General Medicine |
| title | Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_full | Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_fullStr | Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_full_unstemmed | Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_short | Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_sort | safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| title_unstemmed | Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| topic | General Medicine |
| url | http://dx.doi.org/10.1136/bmjopen-2018-026975 |